A Corrective Cosmetic Improves the Quality of Life and Skin Quality of Subjects with Facial Blemishes Caused by Skin Disorders

Background: Facial blemishes resulting from skin disorders have a significant effect on the patient’s self-esteem and impact quality of life (QOL).

Aim: To assess the impact of a corrective cosmetic (CC) on QOL on top of skin quality parameters.

Methods: An international observational study was conducted on subjects with visible facial flaws that would benefit from a corrective cosmetic. Investigators collected data regarding demographics, QOL using the Skindex-16 scale, skin dryness and tautness, subject and investigator satisfaction, cosmetic acceptability and tolerance at baseline and after 4 to 6 weeks of daily use.

Results: A total of 1840 subjects participated; the mean age was 31.5±11.1 and 95% were women. Acne accounted for 48.9% of skin conditions, followed by melasma (16.7%) and rosacea (15.3%). Of the subjects 81.2% had at least 10% of the face affected and the condition was rated as disfiguring by 45.3% of the subjects; 45.0% and 44.4%, respectively, had neither taut nor dry skin at baseline. Baseline Skindex-16 scores for symptoms, emotions, functioning and overall were 1.4±1.3, 3.5±1.6, 2.4±1.8 and 2.4±1.3, respectively, on a scale from 0 to 6. Compliance was 96.0±10.6%. At the end of the study, Skindex-16 scores had significantly (p<0.0001) improved for all parameters, as did skin dryness and tautness. Subject and investigator satisfaction were high or very high; cosmetic acceptability was high or very high and local tolerance good or very good.

Conclusion: The tested corrective cosmetic significantly improved the QOL of subjects with significant facial flaws, skin tautness and dryness, and was well tolerated.

Keywords: corrective cosmetic, dermatoses, quality of life, SKINDEX-16

Introduction

Facial blemishes including acne, angioma, rosacea, hyperpigmentation, vitiligo and other skin disorders may cause psychological impairment. Such impairment may have a significant impact on a patient’s quality of life (QOL), on their relationships with others, self-image, and self-esteem, and may cause depression and/or emotional distress. Several studies have demonstrated that corrective makeup or cosmetic camouflage results in the improvement of QOL in subjects with pigmentation disorders, in particular vitiligo, acne, scars, vascular disorders or after chemotherapy. But these studies were often conducted in small populations.

Despite the proven ability of corrective cosmetics to improve QOL, patients may be discouraged to use them by their healthcare professional as they are still considered as aggravating the condition if not chosen and applied correctly.
The tested highly corrective cosmetic product (Dermablend®️, Vichy Laboratoires, France, hereafter referred to as “CC”) is available in different formulations (3D formulation for acne, containing salicylic acid and eperuline, and stick and fluid corrector formulations for skin conditions other than acne) and shades, and is adapted for each skin type and each indication. Fluid and stick formulations contain mineral filters such as titanium dioxide and iron oxide to protect against UV and visible light. Moreover, it does not affect the structure of the physiological function of the skin, is non-comedogenic, highly photoprotective and safe as reported by Duteil et al and in yet unpublished data.

In 2005, CC was tested for the first time in a small study of 63 subjects with severe facial disorders including acne, dermatosis papulosis, hypopigmentation, lentigines, melasma, rosacea, vascular proliferations or other facial scars. Results after 3 months showed a significant (p<0.01) improvement in Skindex-16 scores.

The aim of the present study was to confirm the improvement in QOL in a large panel of subjects with facial blemishes due to skin disorders, after a period of 4 weeks. Moreover, the study assessed subject and investigator satisfaction, cosmetic acceptability, skin quality and tolerance of the CC.

**Methodology**

Between January and November 2018, a large, international, prospective, anonymous, non-interventional and observational survey assessed the impact of a CC on QOL, using the Skindex-16, as well as on skin dryness and tautness.

The Skindex-16 is an abbreviated version of the Skindex-29 and is composed of 16 questions to which a majority of patients would have chosen the same response when responding to Skindex-29, and measurement of bother rather than frequency of patient experiences. It evaluates symptoms, emotional well-being, and functioning on a scale ranging from 0=not bothered at all to 10=very much bothered.

The survey was conducted according to the guidelines of the International Epidemiological Association for proper conduct in epidemiological research and required in Europe no ethics committee approval for this type of investigation; subjects gave written informed consent to participate in this survey.

Adult subjects with visible facial flaws including, but not limited to, acne, rosacea, hyperpigmentation, angioma or vitiligo and who could benefit from CC were invited to participate. At baseline, investigators proposed one of the different formulas of the CC according to their indication and instructed the subjects to apply the CC once daily on the entire face.

Demographics, QOL, skin dryness and tautness were assessed at baseline. Subject and investigator satisfaction, cosmetic acceptability, application frequency and tolerance were assessed at baseline and after 4 weeks.

Statistical analyses were conducted using SAS software (version 9.4, SAS Institute Inc., Cary, NC). Qualitative variables were described as numbers and percentages of the different response modalities. A 95% confidence intervals were calculated if necessary. Quantitative variables were described as numbers, means, standard deviations, medians, minimums, maximums and numbers of missing data. Quantitative data evolution was studied by a paired samples t-test or a paired samples Wilcoxon test in case of non-parametric distribution. Multinomial data evolution was studied by a generalized mixed model for multinomial data. All statistical analyses were performed at the 5% significance using 2-sided tests, except normality which was tested at the threshold of 1% using the Shapiro–Wilk test.

**Results**

Overall, 1840 subjects, mainly women (95%, 1704/1793) with a mean age of 31.5±11.1 years participated. The acne accounted for 48.9% (900/1840) of subjects with skin conditions. The other diagnoses included 16.7% (307/1840) of subjects with melasma, 15.3% (282/1840) with rosacea, 14.8% (272/1840) with post-inflammatory hyperpigmentation and 9.7% (178/1840) with angioma; other skin conditions (such as vitiligo, hypopigmentation, etc.) impacted 5% or less of the subjects. A total of 81.2% (1489/1840) had at least 10% of the face affected, 45.3% (827/1826) considered the condition as disfiguring; 18.4% had taut and 21.2%, had dry skin. Detailed demographic and skin characteristics at baseline are provided in Table 1. Baseline Skindex-16 scores for symptoms, emotions, functioning and globally were 1.4 ±1.3, 3.5±1.6, 2.4±1.8 and 2.4±1.3, respectively (Table 2).

One subject aged 12 years accounted for demographic data analysis but was excluded from the benefit analysis. This subject was considered a protocol violator.

Overall, 81.6% (1446/1773) applied the CC once daily after 4 weeks, Skindex-16 scores had significantly (p<0.0001) improved by 0.7, 1.8, 1.4 and 1.3 points for symptoms, emotions, functioning and globally, respectively (Figure 1). The prevalence of subjects with skin tautness had decreased by...
14.8% to 3.6% and by 16.5% to 4.7% for those with dry skin (Figure 2); differences were statistically significant (p<0.0001). Subject satisfaction was 8.8±1.4 on an 11-point scale; 98.7% (161/163) of the investigators were satisfied or highly satisfied with the CC. According to the latter, CC had a satisfying or very satisfying impact on the well-being of subjects with acne (95.8%, 159/166), rosacea (95.7%, 132/138), hypopigmentation (95.1%, 117/123), hyperpigmentation (94.1%, 144/153) and angioma (88.9%, 80/90). In total, 95.0% (1741/1835) of all subjects were satisfied or highly satisfied with the cosmetic quality of the tested CC and 96.0% (1761/1835) stated that the CC had met their expectations.

Local tolerance was excellent in 97.7% of all subjects.

Discussion

Results from our study confirmed in a large cohort of subjects with facial blemishes caused by skin disorders that the tested CC significantly (p<0.0001) improved QOL for symptoms, emotions, functioning and globally with greater improvements in emotions and functioning probably explained by the conditions treated. Moreover, the CC hydrated the skin and reduced skin tautness. Subject and investigator satisfaction after 4 weeks of use was very high and subjects highly appreciated the cosmetic quality of their CC.

**Table 1** Demographic and Skin Characteristics at Baseline

| Parameters                  | Values                        |
|-----------------------------|-------------------------------|
| **Gender (n, %)**           |                               |
| Male                        | N=1793                        |
| Female                      | 1704 (95.0%)                  |
| **Age (years)**             |                               |
| Mean±SD                     | 31.5±11.1                     |
| Min;Max                     | 12.0;78.0                     |
| **Age distribution (n, %)** |                               |
| < 20 years                  | 254 (14.0%)                   |
| 20–29                       | 641 (35.4%)                   |
| 30–39                       | 500 (27.6%)                   |
| ≥40                         | 416 (23.0%)                   |
| **Skin condition (n, %)**   |                               |
| Acne                        | 900 (48.9%)                   |
| Rosacea                     | 282 (15.3%)                   |
| Other inflammatory skin diseases | 32 (1.7%)          |
| Vitiligo                    | 97 (5.3%)                     |
| Other hypopigmentation      | 93 (5.1%)                     |
| Melasma                     | 307 (16.7%)                   |
| Post-inflammatory hyperpigmentation | 272 (14.8%)     |
| Other hyperpigmentation     | 104 (5.7%)                    |
| Angioma                     | 178 (9.7%)                    |
| Scars                       | 223 (12.1%)                   |
| Other skin conditions       | 46 (2.5%)                     |
| **Surface of face affected (n, %)** |                   |
| <10%                        | 344 (18.8%)                   |
| 10–29%                      | 724 (39.5%)                   |
| 30–49%                      | 565 (30.8%)                   |
| 50–80%                      | 167 (9.1%)                    |
| >80%                        | 34 (1.9%)                     |
| **Intensity (n, %)**        |                               |
| Minor flaw                  | 999 (54.7%)                   |
| Disfiguring flaw            | 670 (36.7%)                   |
| Very disfiguring flaw       | 144 (7.9%)                    |
| Extremely disfiguring flaw  | 13 (0.7%)                     |
| **Taut skin (n, %)**        |                               |
| Not at all                  | 826 (45.0%)                   |
| Not much                    | 672 (36.6%)                   |
| Yes                         | 301 (16.4%)                   |
| Yes, very taut              | 37 (2.0%)                     |
| **Dry skin (n, %)**         |                               |
| Not at all                  | 814 (44.4%)                   |
| Not much                    | 631 (34.4%)                   |
| Yes                         | 347 (18.9%)                   |
| Yes, very dry               | 41 (2.2%)                     |

**Note:** More than one skin condition possible by subject.

**Table 2** Skindex-16 Scores at Baseline

| Skindex-16 score                  | Values                        |
|-----------------------------------|-------------------------------|
| **Symptoms**                      |                               |
| Mean±SD                           | N=1836                        |
| Min;Max                           | 1.4±1.3                       |
| Median                            | 0.0;6.0                       |
| **Emotions**                      |                               |
| Mean±SD                           | N=1833                        |
| Min;Max                           | 3.5±1.6                       |
| Median                            | 0.0;6.0                       |
| **Functioning**                   |                               |
| Mean±SD                           | N=1831                        |
| Min;Max                           | 2.4±1.8                       |
| Median                            | 0.0;6.0                       |
| **Global Score**                  |                               |
| Mean±SD                           | N=1831                        |
| Min;Max                           | 2.4±1.3                       |
| Median                            | 0.0;6.0                       |

**Note:** Scores ranging from 0=not bothered to 10=very much bothered.
Specific corrective cosmetics and camouflage makeup are becoming more and more popular in the adjuvant care of facial blemishes resulting from primary (acne rosacea vitiligo, melasma) or secondary skin disorders (post-inflammatory hyperpigmentation, blemishes and disorders resulting from adverse reactions or side effects from therapies such as cancer or aesthetic surgery, scars) as they have been shown to improve skin aspect as well as QOL and self-esteem.\textsuperscript{16-22}

However, certain products have only been developed to be specific to a particular type of facial blemish and to different skin phototypes.\textsuperscript{8,18,22} The tested highly corrective CC has been developed to suit all types of facial blemish and different skin phototypes. Moreover, it can be used in women, men and children, due to its excellent local tolerance. And it has shown to have a very high protection against visible light, now well recognized to induce or worsen pigmentation disorders.\textsuperscript{12}

Despite these advantages, and even though camouflage make-up and corrective cosmetics are indicated for any gender and any age, our survey shows that a large majority of CC users are young women.\textsuperscript{23} This may be due to the fact that women care much more about physical aspects and may use makeup more easily than men. Regardless of this potential limitation, our data confirm the significant positive impact of the tested CC on the QOL of subjects with significant facial blemishes.

In conclusion, dermatologists should continue encouraging their patients regardless of gender or age with disfiguring dermatoses to use corrective cosmetics, thus improving skin appearance, well-being and their QOL.

**Acknowledgments**

The authors acknowledge the participation of the study investigators and of the participants and Karl Patrick Göritz, SMWS France, for writing support.

**Funding**

This study was funded by Laboratoires Vichy, France.

**Disclosure**

Delphine Kerob is an employee of Laboratoires Vichy, France. Catherine Delva is an employee of Sylia-Stat. The authors report no other conflicts of interest in this work.
References

1. Sanclemente G, Burgos C, Nova J, et al. The impact of skin diseases on quality of life: a multicenter study. Acta Dermosifiliogr. 2017;108 (3):244–252. doi:10.1016/j.ad.2016.11.008

2. Kornhaber R, Visentin D, Thapa DK, et al. Cosmetic camouflage improves quality of life among patients with skin disfigurement: a systematic review. Body Image. 2018;27:98–108. doi:10.1016/j.bodyim.2018.08.004

3. Levy LL, Emer JJ. Emotional benefit of cosmetic camouflage in the treatment of facial skin conditions: personal experience and review. Clin Cosmet Investig Dermatol. 2012;5:173–182. doi:10.2147/CCID.S33860

4. Korichi R, Pelle-de-Queral D, Gazano G, Aubert A. Why women use makeup: implication of psychological traits in makeup functions. J Cosmet Sci. 2008;59(2):127–137.

5. Seife S, Deshayes P, Dreno B, et al. Interest of corrective makeup in the management of patients in dermatology. Clin Cosmet Investig Dermatol. 2012;5:123–128. doi:10.2147/CCID.S33172

6. Boehncke WH, Ochsendorf F, Paeslack I, Kaufmann R, Zollner TM. Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases. Eur J Dermatol. 2002;12(6):577–580.

7. Draelos ZD. Colored facial cosmetics. Dermatol Clin. 2000;18 (4):621–631. doi:10.1016/S0733-8635(05)70213-8

8. Tanioka M, Yamamoto Y, Kato M, Miyachi Y. Camouflage for patients with vitiligo vulgaris improved their quality of life. J Cosmet Dermatol. 2010;9(1):72–75. doi:10.1111/j.1651-2130.2009.01184.x

9. Ongenae K, Dierckxsens L, Brochez L, van Geel N, Naeyaert JM. Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology. 2005;210(4):279–285. doi:10.1159/000084751

10. Holme SA, Beattie PE, Fleming CJ. Cosmetic camouflage advice improves quality of life. Br J Dermatol. 2002;147(5):946–949. doi:10.1046/j.1365-2133.2002.04900.x

11. Merial-Kieny C, Nocera T, Mery S. [Medical corrective make-up in post- chemotherapy]. Ann Dermatol Venereol. 2008;(1):25–28. French.

12. Dutile L, Esaulea J, Maubert Y, et al. A method to assess the protective efficacy of sunscreens against visible light-induced pigmentation. Photodermatol Photoimmun Photomed. 2017;33 (5):260–266. doi:10.1111/pph.12325

13. Balkrishnan R, McMichael AJ, Ju YJ, et al. Corrective cosmetics are effective for women with facial pigmentation disorders. Cutis. 2005;75 (3):181–187.

14. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105–110. doi:10.1007/BF02738663

15. IEA. International epidemiological association: good epidemiological practice (GEP). IEA guidelines for proper conduct in epidemiological research. November 2007. Available from: http://teaweb.org/good-epidemiological-practice-gep/. Accessed January 8, 2019.

16. Wakeda T, Okamura T, Kawahara T, Heike Y. Camouflage makeup improves quality of life in cancer patients with treatment-related skin changes. Tumori. 2019:008991619867844.

17. Filinte GT, Akoz T. Camouflage therapy in aesthetic surgery. Clin Dermatol. 2014;32(6):813–816. doi:10.1016/j.clderm.2014.02.021

18. Hassain C, Porto DA, Hamzavi I, Lim HW. Camouflaging agents for vitiligo patients. J Drugs Dermatol. 2016;15(4):384–387.

19. Draelos ZD. Cosmeceuticals for rosacea. Clin Dermatol. 2017;35 (2):213–217. doi:10.1016/j.clderm.2016.10.017

20. McMichael L. Skin camouflage. BMJ. 2012;344:d7921. doi:10.1136/ bmj.d7921

21. Mee D, Wong BJ. Medical makeup for concealing facial scars. Facial Plast Surg. 2012;28(5):536–540. doi:10.1055/s-00000018

22. Monfrecola G, Cacciapuoti S, Capasso C, Delfino M, Fabbrocini G. Tolerability and camouflaging effect of corrective makeup for acne: results of a clinical study of a novel face compact cream. Clin Cosmet Investig Dermatol. 2016;9:307–313. doi:10.2147/CCID.S115192

23. Salsberg JM, Weinstein M, Shear N, Lee M, Pope E. Impact of cosmetic camouflage on the quality of life of children with skin disease and their families. J Cutan Med Surg. 2016;20(3):211–215. doi:10.1177/1203475415595175